GMP Compliance: Canada’s Food and Drugs Act

In brief:

• – Health Canada has harmonized Good Manufacturing Practices standards with the Pharmaceutical Inspection Co-operation Scheme (PIC/S) to ensure international alignment
• – Non-compliance can be disastrous for pharma companies, with widespread implications including costly recalls, lost market trust, and license suspensions
• – Digital recordkeeping and automated audit trails are now the industry standard for risk mitigation

What are the current Food and Drugs Act pharma requirements?

Pharmaceutical manufacturing in Canada requires rigorous adherence to Good Manufacturing Practices (GMP) to guarantee that drugs are consistently produced and controlled according to quality standards.

It’s business-critical to understand the GMP core requirements to stay on the correct side of the law. Under the Food and Drugs Act pharma regulations, specifically Division 2, manufacturers must ensure every stage of production is controlled and documented.

This covers the entire chain, as outlined in the Good manufacturing practices guide for drug products (GUI-0001) from “the moment the raw materials enter your plant to the time you release the finished dosage form for sale and distribution”.

The Health Canada GMP framework covers several critical pillars:

1. 1. Premises and sanitation: Facilities must be designed to prevent cross-contamination
2. 2. Equipment validation: All machinery must be qualified and maintained to perform its intended function consistently
3. 3. Raw material testing: This is to confirm the identity of the raw material and that they have the correct properties for the specific manufacturing process
4. 4. Manufacturing control: Every person required must have written procedures to ensure that each lot or batch of the drug is fabricated, packaged/labeled and tested in compliance with those procedures
5. 5. Personnel and training: Staff must possess the technical qualifications and ongoing GMP training best practices to execute standard operating procedures
6. 6. Documentation: Robust and audit-trail ready recordkeeping includes batch records, stability testing data, and raw material specifications

As of 2025, Health Canada transitioned to full harmonization with PIC/S. This means GMP compliance Canada now mirrors global expectations.

This makes this GMP guide for manufacturers in 2026 a vital resource for those exporting to international markets while simultaneously building mutual confidence and harmonized technical requirements.

How long must pharma records be retained?

As per the Food and Drug Regulations (C.02.021), records must typically be kept for at least one year after the expiration date of the lot or batch (except where licence requirements specify otherwise). However, many firms opt for longer retention to mitigate legal risks.

How do I prepare for GMP inspections in 2026?

Taking a proactive approach to inspection risks and measures is the foundation for successful GMP inspections and meeting quality assurance GMP requirements.

GMP inspection risks

Some of the most common reasons for inspection failures, non-compliance ratings, and Corrective and Preventive Action (CAPA) plans include:

1. 1. Documentation gaps: Common GMP documentation challenges often stem from illegible paper logs or “orphaned” data that lacks a clear audit trail.

2. 2. Contamination lapses: Failures in premises sanitation lead to cross-contamination, microbial contamination, physical contamination, or chemical contamination. This can result in patient safety issues, product recalls, and license suspension threats.

3. 3. Supplier audits: Suppliers that are under-prepared, or worse, not adequately versed in the requirements for GMP compliance in Canada, can have an immediate and significant impact on your company. This situation can result in supply chain disruption, batch quarantines, product recalls, and regulatory risk.

Preventative measures for successful GMP audits and inspection

To stay ahead of inspectors, firms should consider implementing these measures:

• – 30-day CAPA plans: Be ready to submit a Corrective and Preventive Action (CAPA) plan within 30 days of an inspection observation. Read the Canadian Government’s bulletin on how to develop a CAPA.
• – Mock inspection protocols: Regularly simulate Health Canada audits to find documentation gaps before an official investigator does. Use the below checklist to assess your audit readiness.
• – GMP supplier qualification: Your compliance is only as strong as your weakest vendor; regular supplier audits are a mandatory component of GMP compliance in Canada. Under Division 2 of the Food and Drug Regulations, Health Canada requires manufacturers to have a written system for selecting, evaluating, and monitoring their suppliers to ensure that raw materials and APIs consistently meet quality specifications.

Health Canada audit preparation checklist (GUI-0001) for GMP

To prepare for a Health Canada audit under the GUI-0001 guidelines, pharmaceutical manufacturers should focus on the core Divisions of the Food and Drug Regulations.

The following checklist summarizes the critical focus areas that inspectors evaluate to determine your GMP compliance Canada status.

Quality management and systems

• – Pharmaceutical Quality System (PQS): Is there a clearly defined PQS that incorporates Quality Risk Management (QRM) principles?
• – Annual Product Quality Review (APQR): Have you conducted and documented a review of all drug products to verify the consistency of the process?
• – Self-inspection program: Is there a regular internal audit schedule to identify documentation gaps before Health Canada arrives? Learn about internal vs. external audits.

Premises and sanitation (C.02.004)

• – Environmental control: Are production areas segregated from non-production areas to prevent contamination lapses?
• – Surface integrity: Are walls, floors, and ceilings free of cracks and made of non-shedding materials that allow for effective cleaning?
• – Sanitation program: Is there a written program detailing cleaning frequencies, methods, and the specific rodenticides/insecticides used?

Equipment validation (C.02.005)

• – Qualification (IQ/OQ/PQ): Is all equipment qualified for its intended use and supported by a Master Validation Plan?
• – Maintenance logs: Are there timestamped records for all equipment repairs and preventative maintenance?
• – Calibration: Is all measuring and weighing equipment calibrated against certified standards?

Personnel and training (C.02.006)

• -Technical qualification: Does the person in charge of pharmaceutical manufacturing have a university degree in a relevant science?
• – Ongoing training: Can you provide records of GMP training best practices for all staff, including temporary workers and consultants?

Raw material and packaging testing (C.02.009 – C.02.011)

• – Vendor approval: Is there a formal GMP supplier qualification process in place for all API and packaging providers?
• – Sampling protocols: Are raw materials sampled and tested according to approved specifications before being released for production?
• – Quarantine: Are “Released,” “Quarantined,” and “Rejected” materials physically segregated and clearly labeled?

Manufacturing control and records (C.02.012 – C.02.020)

• – Master production documents: Do you have approved, dated, and signed master formulas for every drug and batch size?
• – Audit trails: Do your electronic or paper batch records provide a complete history of the lot, including the signature of every person involved in critical steps?
• – Deviation management: Are all out-of-specification results investigated, documented, and linked to a CAPA plan?

Critical audit tip: The Rule of Three

Health Canada inspectors often look for the Rule of Three:

1. 1. Say what you do: Have a written SOP.
2. 2. Do what you say: Follow that SOP exactly.
3. 3. Prove it: Have the audit trail and documentation to show it happened in real-time.

By aligning your facility with the GMP guide for manufacturers in 2026 and deploying robust and secure mechanisms for data storage and compliant communications, you mitigate license suspension threats and ensure a compliant rating during your next regular inspection.

Best tech for GMP audits

The shift from paper-based systems to digital quality tech solutions is the most effective way to solve GMP documentation challenges. Digitizing processes and recordkeeping has become a non-negotiable, but the good news is there are plenty of great solutions available on the market.

Just in case you needed reminding, here are some headline benefits to digitizing recordkeeping and how it can streamline your GMP audit requirements.

Benefits of digital vs. paper:

1. 1. Unrivaled search capabilities: Tech for GMP audits allows for “searchable” compliance, meaning you can pull a specific batch record in seconds rather than hours.
2. 2. Automated audit trails: Every entry is timestamped, preventing backdating and unauthorized changes.
3. 3. Deviation trackers: Automatically flag out-of-specification results for immediate investigation.
4. 4. Secure data vaults: Protect long-term records from physical damage or unauthorized access.
5. 5. Electronic batch systems (EBS): Under GMP compliance Canada and the Food and Drugs Act pharma regulations, every batch must have a detailed history showing it was made correctly. EBS digitizes this entire process, eliminating a previously laborious task.
6. 6. Efficiency: Electronic systems reduce human error in transcription, which is a leading cause of inspection observations.